Intervention not reported
Linear growth velocity in first year of treatment (cm/y) · children up to 18 years of age with persistent asthma
1 finding from 1 review
Intervention not reported
Change from baseline in height over first year of treatment (cm) · children up to 18 years of age with persistent asthma
1 finding from 1 review
Intervention not reported
Change in height standard deviation score (SDS) in first year of treatment · children up to 18 years of age with persistent asthma
1 finding from 1 review
Intervention not reported
Growth velocity over 12 months (cm/y) (higher is better) · children with persistent asthma
The intervention leads to higher growth velocity over 12 months (cm/y) (higher is better) (high certainty).
1 finding from 1 review
Intervention not reported
Change in height over 3 months (cm) (higher is better) · children with persistent asthma
The intervention showed no clear difference in change in height over 3 months (cm) (higher is better) (moderate certainty).
1 finding from 1 review
Intervention not reported
Change in height over 12 months (cm) (higher is better) · children with persistent asthma
The intervention showed no clear difference in change in height over 12 months (cm) (higher is better) (moderate certainty).
1 finding from 1 review
Intervention not reported
Change in SD scores over 12 months (height) (low change is better) · children with persistent asthma
The intervention showed no clear difference in change in SD scores over 12 months (height) (low change is better) (moderate certainty).
1 finding from 1 review
Intervention not reported
Change in weight over 12 months (kg) (higher is better) · children with persistent asthma
The intervention showed no clear difference in change in weight over 12 months (kg) (higher is better) (low certainty).
1 finding from 1 review
Intervention not reported
Change in BMI over 12 months (kg/m2) (higher is better) · children with persistent asthma
The intervention showed no clear difference in change in BMI over 12 months (kg/m2) (higher is better) (low certainty).
1 finding from 1 review
Intervention not reported
Change in skeletal maturation over 12 months (years) (higher is better) · children with persistent asthma
The intervention may leads to higher change in skeletal maturation over 12 months (years) (higher is… (low certainty).
1 finding from 1 review
Intervention not reported
SGRQ Scores range from 0 to 100, with higher scores indicating more limitations · 18 to 80 years of age with bronchiectasis
The intervention showed no clear difference in SGRQ Scores range from 0 to 100, with higher scores indicating more… (low certainty).
1 finding from 1 review
Intervention not reported
TDI Total scores range from ‐ 9 to +9. The lower the score, the greater the deterioration in severity of dyspnoea, MCID ≥ 1 · 18 to 80 years of age with bronchiectasis
The intervention may leads to higher TDI Total scores range from ‐ 9 to +9. The lower the score, the… (low certainty).
1 finding from 1 review
Intervention not reported
Cough‐free days Percentage of days free of cough · 18 to 80 years of age with bronchiectasis
The intervention may leads to higher cough‐free days Percentage of days free of cough (low certainty).
1 finding from 1 review
Intervention not reported
Hospitalisations, number of participants with 1 or more exacerbations · 18 to 80 years of age with bronchiectasis
The intervention showed no clear difference in hospitalisations, number of participants with 1 or more exacerbations (low certainty).
1 finding from 1 review
Intervention not reported
Exacerbation rates per participant per year · patients with COPD
The intervention probably leads to lower exacerbation rates per participant per year (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality · patients with COPD
The intervention leads to lower mortality (high certainty).
1 finding from 1 review
Intervention not reported
Pneumonia · patients with COPD
The intervention showed no clear difference in pneumonia (low certainty).
1 finding from 1 review
Intervention not reported
Hospitalisations due to COPD exacerbations · patients with COPD
The intervention showed no clear difference in hospitalisations due to COPD exacerbations (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events－serious Fluticasone/salmeterol (FPS) versus fluticasone (FP) · patients with COPD
The intervention showed no clear difference in adverse events－serious Fluticasone/salmeterol (FPS) versus… (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events－serious events Budesonide/formoterol (BDF) versus budesonide (BD) · patients with COPD
It is very uncertain whether the intervention changes adverse events－serious events Budesonide/formoterol (BDF) versus… (very low certainty).
1 finding from 1 review